- Overview
- Interactive Chart
- Performance
- Risk and Rating
- Portfolio
- Management Team
- Fee
- Historical Price &
Dividend - Print
- Key Fact Statement
- Glossary
|
Performance History | 30/06/2025 |
Growth of 1,000(CNY) | Advanced Graph |
|
• | Fund | 11.29 | 3.39 | 4.25 | 4.91 | -2.57 |
• | +/-Cat | 5.61 | 11.04 | -0.49 | 2.82 | -3.32 |
• | +/-Idx | 0.22 | 3.78 | -1.43 | 0.75 | -2.00 |
Category: Sector Equity Healthcare | ||||||
Index: Morningstar Global Healthcare NR USD | ||||||
Trailing Returns | 04/07/2025 | |||||
Fund | +/-Idx | |||||
YTD | -1.72 | -1.51 | ||||
3 Years | 15.66 | -2.78 | ||||
5 Years | 25.36 | -1.28 | ||||
10 Years | 105.68 | 4.08 | ||||
12 Month Yield | 0.00 | |||||
Dividend Paying Frequency | - | |||||
Key Stats | ||
Morningstar Category
Sector Equity Healthcare
Morningstar Rating™

ISIN
LU0122379950
NAV 04/07/2025
USD 66.4100
Day Change
0.20%
Total Net Assets (mil)
30/06/2025
USD 12529.53
USD 12529.53
Front Load Fee
3.00%
Deferred Load Fee
-
Manager Name
Xiang Liu
Erin Xie
Inception Date
06/04/2001
Benchmark | ||||
|
||||
Investment strategy |
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. |
Portfolio Profile | 31/05/2025 |
Morningstar Style Box®_Morningstar: | |||||
Equity Style | |||||
![]() |
|||||
Asset Allocation % | |||
% Long | % Short | % Net Assets | |
Stocks | 97.56 | 0.00 | 97.56 |
Bonds | 0.04 | 0.00 | 0.04 |
Cash | 3.05 | 0.78 | 2.27 |
Other | 0.14 | 0.00 | 0.14 |
|
|
Top 5 Holdings | Sector | % |
![]() |
![]() |
6.85 |
![]() |
![]() |
5.81 |
![]() |
![]() |
5.11 |
![]() |
![]() |
5.06 |
![]() |
![]() |
4.89 |
![]() | ||
![]() ![]() ![]() |
||
For the market value of financial derivatives, Morningstar's calculation method includes the nominal value of derivative agreements to reflect position-holding (position) for your reference. If the position-holding ranking calculated by Morningstar shall be different from that published by the fund company, the ranking in the monthly report (click here) by the fund company shall prevail. |
Price Chart
- BlackRock Global Funds – World Healthscience Fund (USD-RMB)

to
Annual Returns | 30/06/2025 | |||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
Total Return | 10.69 | 26.17 | 7.02 | 11.29 | 3.39 | 4.25 | 4.91 | -2.57 |
+/- Category | 8.75 | 2.68 | -6.79 | 5.61 | 11.04 | -0.49 | 2.82 | -3.32 |
+/- Index | 3.88 | 1.71 | -2.48 | 0.22 | 3.78 | -1.43 | 0.75 | -2.00 |
% Rank (Rel to Cat) | 11 | 32 | 58 | 41 | 14 | 62 | 30 | - |
Trailing Returns | 04/07/2025 | |||
Total Return | +/- Category | +/- Index | ||
1 Day | 0.25 | -0.03 | 0.40 | |
1 Week | 0.69 | -0.30 | -0.08 | |
1 Month | 0.56 | -0.81 | -0.95 | |
3 Months | -2.27 | -6.15 | 1.07 | |
6 Months | -1.82 | -4.56 | -0.82 | |
YTD | -1.72 | -4.76 | -1.51 | |
1 Year | -7.49 | -7.88 | -3.56 | |
3 Years | 15.66 | 3.38 | -2.78 | |
5 Years | 25.36 | 9.43 | -1.28 | |
10 Years | 105.68 | 30.86 | 4.08 | |
Category:Sector Equity Healthcare | ||||
Index:Morningstar Global Healthcare NR USD |
Quarterly Returns | 30/06/2025 | |||
Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
2025 | 3.35 | -5.73 | - | - |
2024 | 10.44 | 2.46 | -1.25 | -6.11 |
2023 | -3.00 | 8.55 | -2.32 | 1.35 |
2022 | -3.70 | -1.83 | 0.37 | 8.97 |
Dividend | 04/07/2025 |
12 Month Yield | 0.00 |
Morningstar Rating™ Relative to Category | 30/06/2025 |
3-Year |
![]() |
5-Year |
![]() |
10-Year |
![]() |
Overall |
![]() |
Volatility Measurements | 30/06/2025 | |||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Investment Style Details | 31/05/2025 | |||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Category: Sector Equity Healthcare | ||||||||||||||||||||||||||||||||||||||||
AssetAllocation | 31/05/2025 |
|
|
World Regions | 31/05/2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Category: Sector Equity Healthcare |
Stock Sector Weightings | 31/05/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Category: Sector Equity Healthcare |
Top 10 Holdings | 31/05/2025 |
Portfolio | |
Total Number of Equity Holdings | 82 |
Total Number of Bond Holdings | 7 |
Assets in Top 10 Holdings % | 44.31 |
Product Name | Sector | Country/Region | % of Assets | ||
![]() |
![]() |
United States | 6.85 | ||
![]() |
![]() |
United States | 5.81 | ||
![]() |
![]() |
United States | 5.11 | ||
![]() |
![]() |
United States | 5.06 | ||
![]() |
![]() |
United States | 4.89 | ||
![]() |
![]() |
United Kingdom | 4.28 | ||
![]() |
![]() |
United States | 3.85 | ||
![]() |
![]() |
Switzerland | 3.33 | ||
![]() |
![]() |
United States | 2.63 | ||
![]() |
![]() |
United States | 2.51 | ||
![]() ![]() ![]() |
|||||
Category: Sector Equity Healthcare | |||||
For the market value of financial derivatives, Morningstar's calculation method includes the nominal value of derivative agreements to reflect position-holding (position) for your reference. If the position-holding ranking calculated by Morningstar shall be different from that published by the fund company, the ranking in the monthly report (click here) by the fund company shall prevail. |
Management Team | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Biography | |||||||||||||||||||||||||||||
Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000. | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Biography | |||||||||||||||||||||||||||||
Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999. |
Fees and Expenses | ||||||||||||
|
Disclaimer and Important Notes:
- Wealth Management Products are not deposits and have investment risks, and customers should be cautious in making any investment.
- Structured Deposit is different from ordinary deposits and has investment risks, and customers should be aware of the investment risk and cautious in making any investment.
- The relevant information and data displayed in the pages are for reference only and are those of the offshore funds, under Participation Non-Principal Protected Structured Investment Product, invested by QDII product-overseas fund series issued by DBS China, as well as of the onshore funds distributed by DBS China (as the case may be). Unless otherwise specified, all content in the webpages is provided by Morningstar Shenzhen Ltd (“Morningstar”), and it is possible to be modified without any notice. Some information provided by Morningstar to the pages may differ from the original data due to technical or operational reasons. DBS Bank (China) Limited (“DBS China”) has not verified, monitored or endorsed any content on any page and will not give any guarantee or warranty of whatsoever nature in respect of the correctness, completeness, or timeliness of any content on any page.
- Nothing on this page shall constitute an offer or invitation or solicitation to subscribe any product or fund or to enter into any transaction. The content on this page does not have regard to the specific investment objectives, financial situation or particular needs of any specific person and is not intended to provide, and should not be relied upon for accounting, legal or tax advice, or investment recommendations and is not to be taken in substitution for the exercise of judgment by the reader, who should obtain separate legal or financial advice. DBS China does not act as an adviser or assume any fiduciary responsibility or liability for any consequences financial or otherwise.
- Investment involves risks and the risk of loss from investment can be substantial. Opinions and estimates are subject to change without notice. Any past performance, projection, forecast or simulation of results is not necessarily indicative of the future or likely performance of any investment. Before entering into any transaction or making a commitment to purchase any product mentioned on this page, the reader should take steps to ensure that the reader understands the transaction and has made an independent assessment of the appropriateness of the transaction in the light of the reader’s own objectives and circumstances. In particular, the reader should read all relevant documentation pertaining to the product (including but not limited to product offering documents, term sheets, prospectuses or other similar or equivalent offer or issue documents, as the case may be) and may wish to seek advice from a financial or other professional adviser or make such independent investigations as the reader considers necessary or appropriate for such purposes. If the reader chooses not to do so, the reader should consider carefully whether any product mentioned in the webpages is suitable for him. DBS China shall not assume any liability for any loss or damage (whether direct or indirect) of any person arising out of or in connection with any error, omission, delay and/or reliance on any content of any page.
Terms & Conditions |
Personal Information and Privacy Protection Policy |
© 2013 DBS Bank Ltd
| Co. Reg. No. 196800306E